(0.62%) 5 049.49 points
(0.61%) 38 133 points
(1.07%) 15 772 points
(0.23%) $79.18
(5.59%) $2.04
(-0.03%) $2 310.40
(0.38%) $26.85
(0.91%) $963.55
(0.01%) $0.933
(-0.18%) $11.01
(0.04%) $0.799
(-1.36%) $91.99
Live Chart Being Loaded With Signals
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs)...
Stats | |
---|---|
Dagens volum | 10.80M |
Gjennomsnittsvolum | 4.95M |
Markedsverdi | 5.51B |
EPS | $0 ( 2024-02-28 ) |
Neste inntjeningsdato | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -22.44 |
ATR14 | $0.517 (1.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-11 | Blumenkranz Mark S. | Sell | 32 088 | Common Stock |
2023-07-11 | Blumenkranz Mark S. | Sell | 7 500 | Restricted Stock Units |
2023-07-11 | Blumenkranz Mark S. | Sell | 31 000 | Stock Option (Right to Buy) |
2023-07-11 | Blumenkranz Mark S. | Sell | 15 500 | Stock Option (Right to Buy) |
2023-07-11 | Blumenkranz Mark S. | Sell | 23 186 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-97.75 |
Last 100 transactions |
Buy: 73 584 | Sell: 6 010 653 |
Volum Korrelasjon
Iveric Bio Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
APLS | 0.867 |
PT | 0.861 |
INZY | 0.859 |
BLPH | 0.856 |
IMRX | 0.852 |
LFST | 0.848 |
LNTH | 0.846 |
AFINP | 0.844 |
GEOS | 0.843 |
BMEA | 0.842 |
10 Mest negative korrelasjoner | |
---|---|
CFFN | -0.899 |
ONEM | -0.88 |
SASR | -0.871 |
PFBC | -0.87 |
PBFS | -0.864 |
WABC | -0.858 |
SLN | -0.856 |
ISTR | -0.851 |
CMBM | -0.849 |
DZSI | -0.847 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Iveric Bio Inc Korrelasjon - Valuta/Råvare
Iveric Bio Inc Økonomi
Annual | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-1.450 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-1.450 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.120 |
FY | 2020 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.140 |
Financial Reports:
No articles found.
Iveric Bio Inc
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.